Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 4, 2007 Billy Fisher	In Search of New Prey at FoxHollow The medical device maker reported a 6% increase in revenues on a year-over-year basis for its first-quarter. Investors, take note.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool February 15, 2007 Billy Fisher	Taking FoxHollow's Pulse The medical-device maker gets a checkup from the market. Results were mixed, although the stock was trading down 4%.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.
The Motley Fool March 2, 2005 Brant David McLaughlin	Merck's Road to Recovery Merck didn't get to where it is by being shortsighted, and management has no plans to start now. Investors would be wise not to take on an excessively negative attitude toward the company in the wake of some dark news.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
The Motley Fool February 21, 2006 Rick Aristotle Munarriz	Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes.
Chemistry World August 24, 2012 Andrew Turley	Merck KGaA buys cell culture company Merck KGaA has struck a deal to buy German company Biochrom, which makes cell culture media and buffer solutions, for an undisclosed price.
The Motley Fool November 30, 2004 Rich Smith	Merck Execs Circle the Wagons Shareholder anger is elicited by a filing that Merck made with the Securities and Exchange Commission, announcing that in anticipation of a possible hostile takeover, its executives are taking all possible measures to protect... themselves.
The Motley Fool September 28, 2004 Brian Gorman	Fat Profits? Nastech makes a deal with Merck to develop an obesity drug.
Pharmaceutical Executive January 1, 2006 Jeannette Park	Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future.
The Motley Fool January 31, 2005 Stephen D. Simpson	Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break.
The Motley Fool April 17, 2007 Brian Lawler	Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool April 29, 2004 Brian Gorman	Merck, Bristol-Myers Team Up Their agreement to commercialize a diabetes drug reflects intense sales competition in the industry.
The Motley Fool May 27, 2005 Stephen D. Simpson	Once More With Merck Merck has had a busy spring, but are investors any better off?
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool February 28, 2007 Brian Lawler	Merck's Mighty Future Merck ups its 2007 financial forecast, while positive developments occur for two of its most promising new therapies.
The Motley Fool January 31, 2007 Brian Lawler	Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note.
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
The Motley Fool December 29, 2006 Brian Lawler	Sirna Decides to Take the Cash and Run Shareholders vote to approve Merck's buyout offer. Investors in shares of Merck really have to trust management to have done its due diligence on Sirna and to have faith in its technology.
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool February 24, 2011 Jordan DiPietro	Should You Retire With Merck? Is Merck a good choice for a retirement portfolio?
The Motley Fool February 8, 2008 Brian Orelli	Merck in Lukewarm Water The pharmaceutical's settlement ends a government probe into Medicaid overcharging allegations.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull Rebuttal Priced at a P/E of 13 and paying you a 4.8% dividend, Merck isn't just affordable -- it's a stock you can't afford not to own.
The Motley Fool January 13, 2011 Brian Orelli	This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars.
The Motley Fool October 22, 2008 Brian Orelli	Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013.
The Motley Fool January 10, 2012 Sean Williams	2012 Preview: Merck The biggest question mark facing the pharmaceutical behemoth in 2012 is just how badly it will be affected by losing patent-exclusivity rights on its biggest drug, Singulair.
The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.
The Motley Fool January 27, 2004 Jeff Hwang	Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings.
Chemistry World December 5, 2013 Phillip Broadwith	Merck KGaA snaps up electronic materials specialist The speciality chemicals arm of Merck KGaA has agreed to buy out AZ Electronic Materials for 1.6 billion pounds in cash.
The Motley Fool May 21, 2008 Brian Orelli	OK, Last Vioxx Settlement, Honest! What's another $58 million when Merck's already forking over $4.85 billion?
The Motley Fool September 21, 2006 Brian Lawler	Sayonara, Serono The tiny, struggling drugmaker succumbs to a surprise buyout by German pharmaceutical company Merck KGaA. Investors, take note.
Chemistry World July 1, 2013 Laura Howes	Aspen in $1 billion deal with Merck The deal involves 11 of Merck's drug brands and an active pharmaceutical ingredient business in the Netherlands.
The Motley Fool April 15, 2011 Brian Orelli	Dark Clouds Lift Over Pharma Dispute The case of who bought whom in the Merck -Schering-Plough deal has ended in a draw.
The Motley Fool July 23, 2007 Brian Lawler	Merck Not Hurt Merck repeats another nice quarter of bottom-line growth despite growing concerns about generic competition.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects.
The Motley Fool November 29, 2010 Brian Orelli	There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain.
The Motley Fool August 4, 2006 Stephen D. Simpson	SilverHawk Flying Just Fine, Thanks With med-tech company FoxHollow Technologies, there is growth and risk in equal measure. Investors, take note.
BusinessWeek September 20, 2004 Amy Barrett	Merck: Who Will Revive The Giant? Earnings and new-drug disappointments have investors worried about succession.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
The Motley Fool November 4, 2009 Brian Orelli	An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem.
The Motley Fool February 29, 2008 Brian Orelli	Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years.
Chemistry World September 6, 2012 Andrew Turley	Merck KGaA to cut 1100 German jobs Merck KGaA has announced plans to cut 1100 jobs in Germany -- a 10% reduction in its German workforce. The job cuts will be made by the end of 2015, 'in a socially acceptable manner.
The Motley Fool May 29, 2009 Brian Orelli	Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales.
The Motley Fool May 5, 2006 Stephen D. Simpson	FoxHollow-ed Out Worries about guidance may be giving investors a second crack at this med-tech stock.
The Motley Fool September 18, 2007 Brian Orelli	New York Tag-Teams Merck Both the city and state of New York sue Merck over Vioxx payments, alleging the big pharma defrauded Medicaid and other government agencies, by hiding problems related to its painkilling drug.